Compliance considerations with hormone replacement therapy
- PMID: 9689204
Compliance considerations with hormone replacement therapy
Abstract
Objective: The purpose of this study was to determine women's own reasons for postmenopausal hormone replacement therapy (HRT) utilization and discontinuation in a Turkish population and to investigate the variables that have influenced the compliance to treatment.
Design: The study was comprised of 613 postmenopausal women who presented to the Menopause Unit in the Marmara University Hospital.
Results: A total of 437 women (71.2%) reported that they continued using postmenopausal HRT and 176 women (28.7%) discontinued treatment with an average 4.5 months duration of use (range 1-60 months). Hot flashes was the most common reason for initiating therapy (258 women, 42.0%). Prevention of osteoporosis was mentioned by 149 (24.3%) women as a reason to begin HRT. Bleeding episodes (44.8%) was the most common factor in the patient's decision to discontinue HRT. Continuation of HRT was significantly more common among women who started HRT either because of physician recommendation or osteoporosis concern (p < 0.05). Additionally, a greater percentage of surgically menopausal women began and continued HRT (p < 0.0001) than naturally menopausal women. The educational status of the patients was directly related to incidence of beginning HRT but was not related to the discontinuation of HRT.
Conclusions: Education of menopausal women about the long-term benefits of HRT is critical in improving compliance.
Similar articles
-
The effect of physicians' advice and recommendations on the compliance with hormone replacement therapy in the treatment of postmenopausal symptoms in Japanese women--a prospective study.J Med. 2004;35(1-6):163-9. J Med. 2004. PMID: 18084874
-
Moderate dosage estrogen-androgen therapy improves continuation rates in postmenopausal women: impact of the WHI reports.Climacteric. 2006 Jun;9(3):224-33. doi: 10.1080/13697130600643437. Climacteric. 2006. PMID: 16766436
-
Hormone replacement therapy among Danish women aged 45-65 years: prevalence, determinants, and compliance.Obstet Gynecol. 1997 Aug;90(2):269-77. doi: 10.1016/S0029-7844(97)00264-0. Obstet Gynecol. 1997. PMID: 9241307
-
Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.Climacteric. 2003 May;6 Suppl 1:11-36. Climacteric. 2003. PMID: 12945798 Review.
-
Hormone replacement therapy in postmenopausal women.J Med Invest. 2003 Aug;50(3-4):136-45. J Med Invest. 2003. PMID: 13678382 Review.
Cited by
-
Initiation and discontinuation of hormone therapy for menopausal symptoms: results from a community sample.J Behav Med. 2005 Feb;28(1):105-14. doi: 10.1007/s10865-005-2721-2. J Behav Med. 2005. PMID: 15887880
-
Comparison of piascledine (avocado and soybean oil) and hormone replacement therapy in menopausal-induced hot flashing.Iran J Pharm Res. 2011 Fall;10(4):941-51. Iran J Pharm Res. 2011. PMID: 24250433 Free PMC article.
-
Economic evaluation of norethisterone acetate/ethinylestradiol (FemHRT) for women with menopausal symptoms.Pharmacoeconomics. 2003;21(9):661-9. doi: 10.2165/00019053-200321090-00004. Pharmacoeconomics. 2003. PMID: 12807367
-
Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database.Osteoporos Int. 2003 Oct;14(10):808-13. doi: 10.1007/s00198-003-1431-2. Epub 2003 Sep 11. Osteoporos Int. 2003. PMID: 14523610
-
Misconceptions and beliefs around hormone replacement therapy after childhood hematopoietic stem cell transplantation: A qualitative study among women leukemia survivors.PLoS One. 2023 Apr 11;18(4):e0283940. doi: 10.1371/journal.pone.0283940. eCollection 2023. PLoS One. 2023. PMID: 37040357 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources